ArticleJournal of neuro-oncology2026
Evaluating the efficacy of G12C inhibitors in conjunction with Gamma Knife radiosurgery for KRAS-mutant non-small cell lung cancer brain metastases.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeKRAS G12C mutations occur in approximately 11% of non-small-cell lung cancer (NSCLC) patients and are associated with aggressive disease and poor prognosis. Although KRAS G12C-inhibitors are now approved, their impact on Gamma Knife radiosurgery (GKRS) outcomes remains unexplored. We assessed the safety and efficacy of KRAS G12C inhibitors with GKRS compared with conventional systemic therapies.
methodsSixty-one NSCLC patients with KRAS mutations, thirty-three of which were G12C-mutated (G12C-mut), treated with GKRS from 2011 to 2024 were included. Sixteen received G12C inhibitors (adagrasib, sotorasib or divarasib). Data included demographics, treatment details, prior or concurrent systemic therapies (chemotherapy/IT), and mutational status. Kaplan-Meier analyses were performed to assess overall survival and distant brain failure (DBF) across treatment groups.
resultsAt 12 months, survival rates were highest in non-G12C-mut patients (74%), followed by G12C-mut patients not receiving inhibitors (56%), and lastly those receiving inhibitors (40%). By 36 months, survival rates decreased to 48%, 35%, and 8%, respectively. G12C-mut-on-KRAS inhibitor group exhibited a significantly shorter time to distant brain failure (median = 4 months) compared to those not receiving inhibitors (median = 6.5 months) and non-G12C-mut patients (median = 13 months, p = 0.0031). Local failure and adverse radiation effect rates did not differ significantly among the three cohorts (p > 0.9).
conclusionAdding KRAS G12C-inhibitors to GKRS for G12C-mut NSCLC brain metastases did not improve survival and was linked to earlier DBF. Despite systemic activity, these agents may offer limited CNS-specific benefit versus EGFR/ALK therapies, warranting further investigation to optimize sequencing and patient selection.
Indexed as
Identifiers
42098425What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.